---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-060232"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2026-05-13T20:06:07+00:00"
generated_at: "2026-05-13T20:08:32.035271+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M

## Summary
- Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.
- Net loss narrowed to $2.2M ($0.08 loss per share) from $4.1M ($0.18 loss per share) YoY.
- Adjusted EBITDA turned positive at $0.6M ($0.02 per share) vs negative $0.9M in Q1 2025.
- Cash increased to $27M; gross margin 61% impacted by $1.3M non-cash API write-down.
- SG&A down $0.5M to $10.1M due to lower Emrosi launch costs.

## SEC filing metadata
- accession: 0001104659-26-060232
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2026-05-13T20:06:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/0001104659-26-060232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-060232
- JSON: https://secwatch.observer/filing/0001104659-26-060232.json
- Plain text: https://secwatch.observer/filing/0001104659-26-060232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.